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Background
Patients with metabolic syndrome exhibit generalized
endothelial dysfunction with decreased NO production
and increased vascular oxidative stress. We postulated that
chronic treatment with sildenafil could upregulate the
NOS/cGMP pathway and improve endothelial function in
fructose-fed rats.
Materials and methods
Wistar rats (n = 10–14 per group) were fed a standard
chow (CONT) or a 60% fructose/5% fat (% by weight)-
enriched diet for 8 weeks (FFR). From week 5 through 8,
sildenafil was administered twice a day (sc, 20 mg/kg,
FFR+SIL), thus reaching clinically relevant plasma concen-
trations circa 20 nM unbound known to give efficacy in
man (Pfizer Inc., data on file), then a 1-week wash-out
period from sildenafil was observed. Isometric tension
studies were performed on isolated aortic and superior
mesenteric arterial (SMA) rings precontracted with
noradrenaline to build concentration-response curves
(CRC) to endothelium-dependent (ACh and A23187)
and -independent (SNP) relaxants in presence of
indomethacin. Urinary 8-isoprostanes (IPT) and plasma
levels of IL-6 and TNF-α were also evaluated.
Results
Relaxations to ACh were reduced in aortas of FFR (10-5 M:
-102.6 ± -2.4% vs -89.2 ± 4.7, p < 0.001) while only
slightly affected in SMA rings. Relaxations to A23187 were
significantly reduced both in aortic and SMA rings of FFR.
In aortas, sildenafil treatment restored normal endothe-
lium-dependent relaxations to ACh (10-5 M: -104.2 ±
3.0%, p < 0.001) even after one week of wash-out from
treatment. In SMA rings, a leftward shift of the CRC to
ACh could be detected (pD2: -8.12 ± 0.11 vs -8.60 ± 0.08,
p < 0.05). Relaxations to A23187 were also restored by
sildenafil in both aortic and SMA rings of FFR. Enhanced
compensatory endothelium-independent relaxations to
SNP in FFR were not modified by sildenafil treatment.
Neither IL-6 nor TNF-α were modified by the fructose or
sildenafil treatment. Urinary IPT levels was normalized by
the sildenafil treatment (FFR: 2.07 ± 0.36 vs CONT:0.95 ±
0.14 vs FFR+SIL: 0.88 ± 0.13 ng/ml/24 h, p < 0.05).
Conclusion
Endothelial dysfunction and oxidative stress associated
with the metabolic syndrome can be reversed in FFR by a
chronic treatment with sildenafil, even 7 days after treat-
ment has ceased. This sustained improvement in endothe-
lial function suggests that chronic administration of
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sildenafil may lead to structural and molecular changes
within the vascular wall that may be of benefit in vascular
cardio-metabolic indications.
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